Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Swedish government under the ALF agreement (ALFGBG-983782, ALFGBG-983782)
- License Information
-
More Information
Article History
Received: 28 August 2025
Accepted: 29 August 2025
First Online: 20 September 2025
Declarations
:
: G.J. has received lecture and advisory board fees from Astra Zeneca, Crinetics and Novo Nordisk, Pharmanovia, Pfizer and Takeda/Shire. D.E. has received lecture fees from Ipsen, Recordati and Pfizer AB. A.M. declares no relevant conflicts of interest.
Free to read: This content has been made available to all.
